selenium sulfide - Profile

What are the generic drug sources for selenium sulfide and what is the scope of patent protection?

Selenium sulfide is the generic ingredient in three branded drugs marketed by Allergan Herbert, Actavis Mid Atlantic, Cosette Pharms Nc, Ivax Pharms, Padagis Us, Pharmobedient Cnsltg, and Chattem, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for selenium sulfide

US Patents:	0
Tradenames:	3
Applicants:	7
NDAs:	7

US Patents and Regulatory Information for selenium sulfide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Herbert	EXSEL	selenium sulfide	LOTION/SHAMPOO;TOPICAL	083892-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Actavis Mid Atlantic	SELENIUM SULFIDE	selenium sulfide	LOTION/SHAMPOO;TOPICAL	084394-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Cosette Pharms Nc	SELENIUM SULFIDE	selenium sulfide	LOTION/SHAMPOO;TOPICAL	086209-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ivax Pharms	SELENIUM SULFIDE	selenium sulfide	LOTION/SHAMPOO;TOPICAL	085777-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: July 24, 2026

Selenium Sulfide: investment scenario and IP/Regulatory fundamentals for the antifungal drug used in dandruff and seborrheic dermatitis

Selenium sulfide is a topical antifungal active ingredient used for hyperproliferative skin conditions and dandruff (seborrheic dermatitis spectrum). The investment profile is dominated by generic economics, fragmented brand competition, and heavy reliance on formulation and manufacturing know-how rather than strong, long-lived patent protection. From a risk-and-return perspective, the core decision hinges on whether a sponsor can secure defensible IP around specific delivery formats (shampoos, lotions, creams) and concentration ranges, while maintaining low cost of goods at scale and meeting FDA labeling expectations for over-the-counter (OTC) and prescription products where applicable.

---

What is selenium sulfide and where is it used commercially?

Selenium sulfide is used in topical anti-dandruff and anti-seborrheic dermatitis regimens. Commercially, it appears primarily as:

• OTC anti-dandruff shampoos (commonly 1% and 2.5% selenium sulfide formulations)
• Some non-shampoo topical dermatology formats depending on market (lotions/solutions)
• Adjunctive use in scalp conditions where Malassezia proliferation is implicated

Mechanism (practical view for investors):

• Selenium sulfide reduces fungal load and normalizes skin turnover processes associated with dandruff/seborrheic dermatitis.
• The market does not depend on a single molecular biomarker or narrow patient subgroup. Demand is cyclical but generally stable, driven by consumer routine grooming and retail distribution.

---

What patents protect selenium sulfide topical products and how strong is the patent estate?

Featured snippet answer: Most selenium sulfide products are unlikely to have meaningful active composition-of-matter protection tied to the active ingredient itself. Defensibility, where present, tends to come from formulation-specific patents, manufacturing methods, and specific container/packaging, not from long-lived new molecular entities.

Patent estate structure investors typically face

For older small-molecule actives like selenium sulfide, the investable IP usually clusters in:

• Formulation patents (vehicle selection, surfactant system, solubilization, viscosity/rheology)
• Concentration-specific compositions (within approved strengths)
• Stabilization and shelf-life (oxidation control, ingredient compatibility)
• Scalp-adhesion or residence-time approaches in shampoo bases
• Manufacturing methods (mixing order, filtration specs, particle control)

Where litigation risk tends to sit

In topical generic-heavy categories, IP disputes often focus on:

• Method-of-use claims (rare for broad OTC dandruff labeling)
• Formulation equivalence in paragraph-IV-style disputes (if any ANDA exists for prescription strengths)
• Trade dress and brand formulation claims, which can be easier to design around

Investment implication: Absent clear, active, enforceable exclusivity around a specific product format and strength, investors generally underwrite defensibility via speed, cost, and distribution, not via patent-backed pricing power.

---

When does selenium sulfide lose exclusivity? What does the exclusivity timeline look like?

Featured snippet answer: Selenium sulfide’s active ingredient is widely available; product exclusivity typically expires long ago, leaving the field dominated by generics and authorized equivalents.

Because selenium sulfide is an older topical active, most investment-relevant exclusivity today comes from:

• Any remaining product-specific exclusivity for particular dosage forms or NDA/505(b)(2) formulations (if they exist for a specific sponsor)
• OTC monograph-related marketing history rather than modern NDA exclusivity frameworks

Investment implication: For new entrants, the exclusivity question is usually “launch now” rather than “wait for a milestone,” unless targeting a niche prescription presentation that still carries sponsor-specific legal protections.

---

What is the Orange Book status of selenium sulfide?

Featured snippet answer: Selenium sulfide is broadly marketed and generally does not present as a single dominant reference listed in a way that confers long-term exclusivity for the active ingredient. Orange Book value is typically limited to specific product entries, strengths, and application types.

How to underwrite Orange Book value in this category

• Look for whether a specific selenium sulfide shampoo/lotion entry lists active patents (composition, formulation, method-of-use) and whether those patents are scheduled to expire in the investment horizon.
• If there are no active listed patents for the exact dosage form and strength, the product economics are effectively generic from a legal standpoint.

Investment implication: Without active Orange Book-listed patents that map cleanly to a targeted product format, the investment case relies on branding, placement, and manufacturing execution.

---

What formulations are protected by patents for selenium sulfide shampoos and lotions?

Featured snippet answer: When patents exist, they most often protect the “how it’s made” and “how it performs in the bottle,” not the active ingredient. For selenium sulfide, that usually means formulation design for:

• stable solubilization or dispersion of selenium sulfide in the shampoo base
• surfactant system compatibility
• viscosity and spreadability
• skin/scalp deposition and residue control

Delivery-format split that matters for investors

• Shampoo: formulation and rheology, plus ability to clear or rinse without excessive residue
• Lotions/solutions: solubilization, spreading, and controlled dripping
• Cream/other (where marketed): stability and penetration-controlled vehicles

Investment implication: If a company can secure formulation exclusivity for a specific strength and base composition, it can delay generic competition. If not, the market quickly commoditizes.

---

How many patents cover selenium sulfide topical products in the US, and what jurisdictions matter most?

Featured snippet answer: There is no single consolidated global “selenium sulfide patent count” that predicts enforceable value, because protection is fragmented by product line, strength, and formulation. For investment decisions, the relevant count is the number of active, enforceable patents tied to the exact US reference product, dosage form, and strength you intend to commercialize.

Jurisdictions investors typically prioritize

• United States: enforceability via US courts; Orange Book mapping to launch timing
• Europe: EP-family patents for formulation/manufacturing, if any; less relevant if no active claims
• Japan and Canada: similar pattern; useful only when EP/US families exist

Investment implication: The “jurisdiction count” is meaningful only if there is an enforceable claim family aligned with your product.

---

What generic entry risks exist for selenium sulfide products?

Featured snippet answer: Generic entry risk is high in practice because selenium sulfide is an old active ingredient with a competitive market structure. The main risks are not “can they file,” but “will they win shelf placement and match consumer expectations at a lower price.”

Key generic-entry friction points

• Formulation equivalence (stability, odor, color, rinse performance)
• Manufacturing control (consistency across batches)
• Packaging compatibility (leak resistance, oxidation exposure)
• Regulatory pathway friction (where applicable)
• Consumer perception (dandruff is a visible outcome; brand loyalty can be sticky, but price sensitivity is real)

Investment implication: For investors, entry risk is primarily commercial: retail/wholesale placement and manufacturing cost, not patent injunction risk.

---

What does biosimilar risk mean for selenium sulfide?

Featured snippet answer: There is no biosimilar risk profile for selenium sulfide. The category is a conventional small-molecule active in topical dermatology. Competition is generic and label-variant focused, not biosimilar driven.

---

What FDA regulatory status applies to selenium sulfide products?

Featured snippet answer: Selenium sulfide is marketed in the US under topical drug frameworks, with OTC dandruff use being a common channel. Regulatory strategy usually centers on:

• maintaining the approved strength and labeling claims
• aligning formulation and manufacturing with regulatory submissions
• meeting quality standards and stability requirements

Regulatory pathways investors usually map

• OTC monograph vs NDA/505(b)(2) vs ANDA: the determining factor is whether a specific product is approved as a drug product and what reference it uses.
• For any targeted prescription product entry, the risk becomes the alignment of active strength, dosage form, and labeling.

Investment implication: Most of the regulatory work is CMC and labeling defensibility rather than clinical development.

---

How does selenium sulfide compare with alternatives in anti-dandruff and seborrheic dermatitis?

Selenium sulfide competes in a crowded OTC dermatology shelf with antifungal and anti-proliferative actives including:

• ketoconazole (OTC or prescription depending on market and concentration)
• zinc pyrithione
• ciclopirox (in some formulations)
• salicylic acid (keratolytic, dandruff control)
• coal tar and other symptomatic actives

Competitive comparison investors should quantify

• Price per treatment
• Net cost of goods (including packaging)
• Consumer preference drivers: smell, residue, perceived efficacy after repeat use

Investment implication: Because actives are interchangeable at the consumer level, differentiation must be executed in formulation, experience, and distribution.

---

Which companies dominate selenium sulfide product categories and how does that affect pricing?

Featured snippet answer: The category is typically dominated by a mix of brand legacy sellers and generic manufacturers, with distribution scale as a key advantage. Pricing tends to compress toward cost-of-goods plus distribution margin once generics gain placement.

Investment implication: Without a clear differentiation edge, entry or expansion tends to be a margin-losing bet unless the firm can undercut costs and secure retailer listings.

---

What is the investment scenario for adding a new selenium sulfide product?

Best-fit investment thesis

• Launch a differentiated formulation (rinse feel, residue control, stability) tied to a defensible niche: a specific strength, scalp-targeted delivery, or targeted bundle.
• Use manufacturing scale and process control to win gross margin before price compression.
• Underwrite distribution execution risk as the primary driver of ROI.

Where ROI typically breaks

• No active legal exclusivity tied to the exact product format and strength
• Differentiation that is not protectable and is quickly copied
• Weak retailer/channel access leading to spend-heavy DTC CAC that destroys unit economics

Capital intensity

Topical actives are usually lower R&D capital than biologics and lower clinical capital than new chemical entities. The investment cost concentrates in:

• formulation development
• stability programs
• scale-up and manufacturing validation
• packaging and labeling work

Investment implication: The most investable angle is speed and execution, not long-hold monopoly pricing.

---

What patent litigation affects selenium sulfide products?

Featured snippet answer: Litigation exists in the category but typically does not revolve around a robust, long-lived active-ingredient patent. Disputes, where they occur, often concern formulation claims, method claims, or packaging/labeling.

Investment implication: Litigation-driven tailwinds (settlements that preserve market share) are harder to predict and should not be the base case for underwriting.

---

What settlement or licensing deals are typical in selenium sulfide?

Featured snippet answer: If licensing occurs, it is usually tied to formulation know-how, manufacturing processes, or specific product presentation rather than broad active-ingredient licensing.

Investment implication: Treat licensing as a defensive tactic to secure market presence for a particular presentation, not as an enduring revenue model across multiple strengths and dosage forms unless the licensed IP is tightly mapped.

---

How strong is selenium sulfide’s “switching barrier” for consumers and retailers?

Featured snippet answer: Switching barriers exist through routine use and perceived efficacy, but they are not as strong as in chronic, precision-dosed therapies. Consumers experiment with actives when results lag.

Investment implication: Retailers and wholesalers respond to sell-through. If a product wins on early efficacy perception and user experience, distribution tends to follow.

---

What are realistic generic launch scenarios for selenium sulfide products?

Featured snippet answer: Launch risk for generic competitors is generally immediate once they can file an appropriate submission and demonstrate quality and bioequivalence where required (topicals often use different comparative standards). The key barrier is not waiting for patent expiration; it is meeting product and labeling requirements quickly.

Scenario framing for investors

• Low-legal-barrier scenario: No active, enforceable patents mapped to your dosage form. Generic competitors enter quickly; pricing compresses.
• Formulation-protected scenario: A formulation-specific patent blocks exact copying. Competitors may design around while still competing at a lower price point.
• Niche-prescription scenario: If a specific prescription presentation has remaining protections, delayed entry is possible, but it is product-specific.

Investment implication: Underwrite to the low-legal-barrier case unless you can map enforceable active claims to the exact product you will sell.

---

Key Takeaways

• Selenium sulfide is a mature, topical antifungal active with market dynamics dominated by generics, retail placement, and manufacturing execution.
• Investment defensibility is more likely to come from formulation and manufacturing IP tied to specific strength and dosage form than from active-ingredient patents.
• Exclusivity and Orange Book value are typically limited for this older active, so base-case economics should assume competitive pricing pressure.
• The primary risk is commercial: differentiation that consumers notice quickly enough to earn shelf space and repeat purchases.

---

FAQs

1) Is selenium sulfide OTC or prescription in the US?

It is commonly available OTC for anti-dandruff use, with prescription exposure depending on specific product approvals, strengths, and labeling in the market.

2) What are the most common selenium sulfide strengths used in shampoos?

Commercial products most often use 1% and 2.5% selenium sulfide concentrations for anti-dandruff use.

3) Can generic manufacturers copy selenium sulfide shampoos easily?

They can generally compete once they can meet quality and regulatory requirements and create a formulation that meets user-expectation benchmarks; patent protection is usually not a strong barrier unless tied to a specific formulation presentation.

4) What differentiates winning selenium sulfide brands in practice?

Product experience (rinse feel, residue control, perceived efficacy timeline) plus distribution execution are typically decisive.

5) Does selenium sulfide face biosimilar competition?

No. It is not a biologic, so competition is generic and label/formulation focused rather than biosimilar driven.

---

References (APA)

1. FDA. (n.d.). Drug approvals and regulatory information. U.S. Food and Drug Administration. https://www.fda.gov/
2. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/